Search Results for "Sunitinib"

17:29 EST 30th November 2015 | BioPortfolio

Matching Channels


Matching News

Chromosomal Changes Predict Clinical Response to Sunitinib in RCC

Clinical response can be challenging to predict in some cancers, but new research has shown the ability to predict CR to sunitinib (Sutent) in patients with advanced renal cell carcinoma (RCC).

Sorafenib, sunitinib may pose cardiovascular risk

(HealthDay)—Older kidney cancer patients treated with sorafenib or sunitinib may face an increased risk of cardiovascular adverse events, according to a study published online Oct. 6 in Cancer.

Celldex begins Phase I/II trial of varlilumab-sunitinib combination to treat CC-RCC

US-based Celldex Therapeutics has started an open-label, Phase I/II safety and tolerability trial evaluating the investigational combination of varlilumab and sunitinib (Sutent) in patients with metas...

Kidney cancer: Sunitinib: 2/1 is superior to 4/2

Kidney cancer: Trebananib plus sunitinib improves survival outcomes

Kidney cancer: Effect of sorafenib and sunitinib on cardiac function

Kidney cancer: Sunitinib is effective in a subset of patients with mRCC

miR-221/222 Are Involved in Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma

Matching PubMed Articles

Prodrug AST-003 Improves the Therapeutic Index of the Multi-Targeted Tyrosine Kinase Inhibitor Sunitinib.

Patients have responded well to the multi-targeted tyrosine kinase inhibitor (TKI) Sunitinib in the clinic. But the severe toxic side effects associated with Sunitinib limit its therapeutic index. To ...

Sunitinib - ibuprofen drug interaction affects the pharmacokinetics and tissue distribution of sunitinib to brain, liver and kidney in male and female mice differently.

Tyrosine kinase inhibitor sunitinib (used in GIST, advanced RCC and pancreatic neuroendocrine tumors) undergoes CYP3A4 metabolism and is an ABCB1B and ABCG2 efflux transporters substrate. We assessed ...

Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.

Vascular endothelial growth factor (VEGF) and mammalian target of rapamycin are well-known therapeutic targets for renal cell carcinoma (RCC). Sunitinib is an agent that targets VEGF receptors and is ...

Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours.

Sunitinib is approved worldwide for treatment of advanced pancreatic neuroendocrine tumours (pNET), but no validated markers exist to predict response. This analysis explored biomarkers associated wit...

Sunitinib in Metastatic Renal Cell Carcinoma: A Systematic Review of UK Real World Data.

Real world data (RWD) are increasingly used to inform drug reimbursement decisions, but it is unclear how well outcomes from real world studies compare to those of clinical trials. This systematic rev...

Search Whole site using Google


Advertisement Advertisement